iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone415-632-5700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$147.29 million
Profitability
Miscellaneous
Employees748
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
Irhythm Technologies (NASDAQ:IRTC) Frequently Asked Questions
What is Irhythm Technologies' stock symbol?
Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."
How were Irhythm Technologies' earnings last quarter?
Irhythm Technologies Inc (NASDAQ:IRTC) posted its quarterly earnings data on Wednesday, July, 31st. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.02. The business earned $53.30 million during the quarter, compared to analyst estimates of $49.89 million. Irhythm Technologies had a negative net margin of 24.45% and a negative return on equity of 76.47%. Irhythm Technologies's revenue for the quarter was up 50.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.51) earnings per share. View Irhythm Technologies' Earnings History.
When is Irhythm Technologies' next earnings date?
What guidance has Irhythm Technologies issued on next quarter's earnings?
Irhythm Technologies updated its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $212-216 million, compared to the consensus revenue estimate of $210.3 million.
What price target have analysts set for IRTC?
8 brokerages have issued 1 year target prices for Irhythm Technologies' stock. Their forecasts range from $75.00 to $125.00. On average, they anticipate Irhythm Technologies' stock price to reach $101.63 in the next twelve months. This suggests a possible upside of 53.0% from the stock's current price. View Analyst Price Targets for Irhythm Technologies.
What is the consensus analysts' recommendation for Irhythm Technologies?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Irhythm Technologies.
What are Wall Street analysts saying about Irhythm Technologies stock?
Here are some recent quotes from research analysts about Irhythm Technologies stock:
- 1. According to Zacks Investment Research, "iRhythm Technologies, Inc. is a digital healthcare company. It focuses on the provision of ambulatory electrocardiogram, monitoring for patients at risk for arrhythmias primarily in the United States. The company offers ZIO Service, a platform which provides wearable biosensor with cloud-based data analytics that distill data from heartbeats into clinically actionable information. iRhythm Technologies, Inc. is headquartered in San Francisco, California. " (10/2/2019)
- 2. Northland Securities analysts commented, "We are introducing our FY20 numbers, with revs @ $263M, up 30% y/y. Our rating remains MP, but our PT changes to $75." (2/13/2019)
Has Irhythm Technologies been receiving favorable news coverage?
Media stories about IRTC stock have trended negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Irhythm Technologies earned a coverage optimism score of -2.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Irhythm Technologies.
Who are some of Irhythm Technologies' key competitors?
Some companies that are related to Irhythm Technologies include Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), NuVasive (NUVA), Tandem Diabetes Care (TNDM), ICU Medical (ICUI), Cantel Medical (CMD), Nevro (NVRO), Glaukos (GKOS), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Inspire Medical Systems (INSP), AtriCure (ATRC) and Orthofix Medical (OFIX).
What other stocks do shareholders of Irhythm Technologies own?
Who are Irhythm Technologies' key executives?
Irhythm Technologies' management team includes the folowing people:
- Mr. Kevin M. King, Pres, CEO & Director (Age 63)
- Mr. Matthew C. Garrett, Chief Financial Officer (Age 51)
- Mr. David A. Vort, Exec. VP of Sales (Age 53)
- Dr. Derrick Sung, Exec. VP of Strategy & Corp. Devel. (Age 46)
- Mr. Karim Karti, Chief Operating Officer (Age 50)
When did Irhythm Technologies IPO?
(IRTC) raised $76 million in an initial public offering on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
Who are Irhythm Technologies' major shareholders?
Irhythm Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Cerebellum GP LLC (0.01%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Merz Cathleen Noel Bairey, Raymond W Scott and Vijay K Lathi. View Institutional Ownership Trends for Irhythm Technologies.
Which major investors are selling Irhythm Technologies stock?
IRTC stock was sold by a variety of institutional investors in the last quarter, including Cerebellum GP LLC. Company insiders that have sold Irhythm Technologies company stock in the last year include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett and Merz Cathleen Noel Bairey. View Insider Buying and Selling for Irhythm Technologies.
How do I buy shares of Irhythm Technologies?
Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Irhythm Technologies' stock price today?
One share of IRTC stock can currently be purchased for approximately $66.44.
How big of a company is Irhythm Technologies?
Irhythm Technologies has a market capitalization of $1.65 billion and generates $147.29 million in revenue each year. The company earns $-48,280,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe.View Additional Information About Irhythm Technologies.
What is Irhythm Technologies' official website?
How can I contact Irhythm Technologies?
Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]
MarketBeat Community Rating for Irhythm Technologies (NASDAQ IRTC)
MarketBeat's community ratings are surveys of what our community members think about Irhythm Technologies and other stocks. Vote "Outperform" if you believe IRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
